On December 25, Gelonghui reported that China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary Qinhuangdao Zizhu Pharmaceutical Co., Ltd. (hereinafter referred to as "Qinhuangdao Zizhu") received the Certificate of Suitability to Monograph of European Pharmacopoeia (hereinafter referred to as "CEP certificate") issued by the European Directorate for the Quality of Medicines & Healthcare (hereinafter referred to as "EDQM") for the Active Pharmaceutical Ingredient of Dienogest (hereinafter referred to as "the Active Pharmaceutical Ingredient").
Dienogest (a fourth-generation progestin) is a mixed progestin that combines the pharmacological advantages of both natural and synthetic progestins. Dienogest exhibits a strong progestogenic effect and anti-androgenic effect in the endometrium, which helps reduce the occurrence of acne and seborrhea, and is used to treat endometriosis.
